1187 related articles for article (PubMed ID: 18183025)
1. A quantitative analysis of kinase inhibitor selectivity.
Karaman MW; Herrgard S; Treiber DK; Gallant P; Atteridge CE; Campbell BT; Chan KW; Ciceri P; Davis MI; Edeen PT; Faraoni R; Floyd M; Hunt JP; Lockhart DJ; Milanov ZV; Morrison MJ; Pallares G; Patel HK; Pritchard S; Wodicka LM; Zarrinkar PP
Nat Biotechnol; 2008 Jan; 26(1):127-32. PubMed ID: 18183025
[TBL] [Abstract][Full Text] [Related]
2. Trends in kinase selectivity: insights for target class-focused library screening.
Posy SL; Hermsmeier MA; Vaccaro W; Ott KH; Todderud G; Lippy JS; Trainor GL; Loughney DA; Johnson SR
J Med Chem; 2011 Jan; 54(1):54-66. PubMed ID: 21128601
[TBL] [Abstract][Full Text] [Related]
3. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
Martin E; Mukherjee P
J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
[TBL] [Abstract][Full Text] [Related]
4. Chemical fragments as foundations for understanding target space and activity prediction.
Sutherland JJ; Higgs RE; Watson I; Vieth M
J Med Chem; 2008 May; 51(9):2689-700. PubMed ID: 18386916
[TBL] [Abstract][Full Text] [Related]
5. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
7. PhosphoPOINT: a comprehensive human kinase interactome and phospho-protein database.
Yang CY; Chang CH; Yu YL; Lin TC; Lee SA; Yen CC; Yang JM; Lai JM; Hong YR; Tseng TL; Chao KM; Huang CY
Bioinformatics; 2008 Aug; 24(16):i14-20. PubMed ID: 18689816
[TBL] [Abstract][Full Text] [Related]
8. A small molecule-kinase interaction map for clinical kinase inhibitors.
Fabian MA; Biggs WH; Treiber DK; Atteridge CE; Azimioara MD; Benedetti MG; Carter TA; Ciceri P; Edeen PT; Floyd M; Ford JM; Galvin M; Gerlach JL; Grotzfeld RM; Herrgard S; Insko DE; Insko MA; Lai AG; Lélias JM; Mehta SA; Milanov ZV; Velasco AM; Wodicka LM; Patel HK; Zarrinkar PP; Lockhart DJ
Nat Biotechnol; 2005 Mar; 23(3):329-36. PubMed ID: 15711537
[TBL] [Abstract][Full Text] [Related]
9. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases.
Graczyk PP
J Med Chem; 2007 Nov; 50(23):5773-9. PubMed ID: 17948979
[TBL] [Abstract][Full Text] [Related]
10. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
Sheinerman FB; Giraud E; Laoui A
J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
[TBL] [Abstract][Full Text] [Related]
11. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity.
Sundstrom TJ; Anderson AC; Wright DL
Org Biomol Chem; 2009 Mar; 7(5):840-50. PubMed ID: 19225663
[TBL] [Abstract][Full Text] [Related]
13. High-throughput biochemical kinase selectivity assays: panel development and screening applications.
Card A; Caldwell C; Min H; Lokchander B; Hualin Xi ; Sciabola S; Kamath AV; Clugston SL; Tschantz WR; Leyu Wang ; Moshinsky DJ
J Biomol Screen; 2009 Jan; 14(1):31-42. PubMed ID: 19073965
[TBL] [Abstract][Full Text] [Related]
14. Toward a pharmacophore for kinase frequent hitters.
Aronov AM; Murcko MA
J Med Chem; 2004 Nov; 47(23):5616-9. PubMed ID: 15509160
[TBL] [Abstract][Full Text] [Related]
15. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
Aronov AM; McClain B; Moody CS; Murcko MA
J Med Chem; 2008 Mar; 51(5):1214-22. PubMed ID: 18288794
[TBL] [Abstract][Full Text] [Related]
16. Kinase selectivity profiling by inhibitor affinity chromatography.
Valsasina B; Kalisz HM; Isacchi A
Expert Rev Proteomics; 2004 Oct; 1(3):303-15. PubMed ID: 15966827
[TBL] [Abstract][Full Text] [Related]
17. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
[TBL] [Abstract][Full Text] [Related]
18. Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index.
Cheng AC; Eksterowicz J; Geuns-Meyer S; Sun Y
J Med Chem; 2010 Jun; 53(11):4502-10. PubMed ID: 20459125
[TBL] [Abstract][Full Text] [Related]
19. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
[TBL] [Abstract][Full Text] [Related]
20. Selectivity assessment of kinase inhibitors: strategies and challenges.
Luo Y
Curr Opin Mol Ther; 2005 Jun; 7(3):251-5. PubMed ID: 15977423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
